Introduction
Classic NMO is defined as the simultaneous occurrence of bilateral optic neuritis and transverse myelitis [1] . NMO spectrum represents a group of neurologic disorders defined by the presence of NMO-IgG involving autoimmunity against aquaporin-4 water channel [2, 3] . NMO-IgG has been incidentally discovered in patients with cancer, possibly reflecting a paraneoplastic immune response [4, 5] . The present work describes a case of a woman diagnosed with metastatic breast cancer and leptomeningeal spread who presented with bilateral optic neuritis and was found to have the NMO-IgG.
Case Report
A 56 year old woman with a history of metastatic breast cancer presented with acute, severe, bilateral vision loss and headache. She had been diagnosed with breast cancer metastatic to the chest wall 18 months ago and had undergone lumpectomy and chemotherapy. Six months prior to current presentation, she was found to have recurrent metastatic breast cancer and had undergone right mastectomy. She refused a full course of chemotherapy secondary to side effects and had not received radiation therapy. She was being treated with Capecitabine. She also had a history of human immunodeficiency virus infection with a viral titer that was undetectable and CD-4 count of 437 mm She was treated with intravenous steroids without significant benefit. Unfortunately, her clinical status continued to deteriorate and she succumbed to multiple complications from
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Neuromyelitis optica (NMO) is an inflammatory disorder of the central nervous system characterized by optic neuritis and transverse myelitis. The identification of NMO IgG ab led to the definition of NMO spectrum disorders. There have been a few reports of NMO spectrum disorders in association with cancers. The present case study describes a woman diagnosed with metastatic breast cancer and leptomeningeal spread who presented with bilateral optic neuritis and who was found to have the NMO-IgG. Reports such as this show that the potential para-neoplastic association should be considered when seeing a patient with an NMO spectrum disorder and in the appropriate clinical setting investigating an underlying cancer might be important. Studies of the diverse presentations of NMO in different clinical settings could lead to a better understanding of the underlying disease mechanisms and can potentially provide targets for therapeutic intervention. 
Discussion
The report describes a 56 year old woman with metastatic breast cancer who presented with bilateral optic neuritis and was found to have the NMO-IgG in her serum. Recurrent metastatic disease was detected during her presentation suggesting a potential association with the malignancy.
NMO has been previously recognized as a possible paraneoplastic phenomenon. In the earliest reported study exploring NMO-IgG in the context of cancers, there were several incidental findings of positive NMO-IgG among patients evaluated for paraneoplastic antibodies and also positive NMO-IgG in patients with known cancers where an NMO spectrum disorder was suspected [5] . NMO-IgG was associated with several cancers including breast, thyroid, carcinoid, pituitary somatotropinoma and B-cell lymphoma. Case reports have described a probable association with lung and thymic cancers and NMO as well [5, 6] .
Several auto antibodies targeting the nervous system have been recognized as para-neoplastic phenomenon and many onconeural antigens have been identified. It is conceivable that NMO-IgG was produced as an immune response to the underlying cancer and with appropriate immune triggers lead to the clinical presentation of an NMO disorder. Another plausible explanation for the patient's presentation when she had a relapse of NMO coinciding with leptomeningeal spread is that she may have been an asymptomatic carrier of NMO-IgG and immune processes elicited by the cancer provided the trigger for the relapse. An earlier report raised this hypothesis when they described an 87 year old man who developed an NMO spectrum disorder after a diagnosis of prostate adenocarcinoma and relapsed after pneumococcal vaccination [7] . It has been demonstrated that NMO-IgG alone does initiate injury but additional factors including break down of the blood brain barrier and perhaps immune mediation by T cell or complement activation is implicated in the pathogenesis. This is the first reported case of an NMO spectrum disorder in a patient with leptomeningeal carcinomatosis. It adds to accumulating evidence that NMO can present as para-neoplastic syndrome. The potential para-neoplastic association should be kept in mind when seeing a patient with an NMO spectrum disorder and in the appropriate clinical setting investigating an underlying cancer might be important. A better understanding of the underlying disease mechanisms can potentially lead to targets for therapeutic intervention.
